QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord 1 Biogen's second rare disease therapy ...
QALSODY is the first therapy designed to address the underlying genetic cause of SOD1-ALS2, a rapidly progressive and uniformly fatal condition that impacts motor function, speech, and respiratory ...
スーパーオキシドジスムターゼ1（SOD1）遺伝子変異がある筋萎縮性側索硬化症（SOD1ALS）患者を対象に、アンチセンスオリゴヌクレオチドtofersen髄腔内投与の有効性を第III相試験で検討（VALOR試験）。主要評価項目は、急速な進行が予測された患者のALS機能評価 ...
HTA assessments highlight importance of timely and equitable access to QALSODY for this ultra-rare genetic form of ALS and urgent need for therapies that slow progression, preserve function and ...
その結果、ほとんどの患者に腰椎穿刺関連の有害事象が見られた。 tofersen群の4例で脳脊髄液（CSF）中の白血球数増加、5例でタンパク質量の増加が有害事象として報告された。 肺塞栓症および呼吸不全による死亡が各1例発生した。
The MarketWatch News Department was not involved in the creation of this content. -- CDA issues positive reimbursement recommendation for QALSODY -- INESSS recognizes QALSODY's promising clinical ...
Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic lateral sclerosis (ALS) compared with delayed treatment, according to data from ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Neurofilament light chain and cerebrospinal fluid ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する
フィードバック